Mechanisms and phenotypic consequences of acquisition of tigecycline resistance by Stenotrophomonas maltophilia

被引:18
|
作者
Blanco, Paula [1 ]
Corona, Fernando [1 ]
Luis Martinez, Jose [1 ]
机构
[1] CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain
关键词
MULTIDRUG EFFLUX PUMP; RIBOSOMAL S10 PROTEIN; CYSTIC-FIBROSIS; ANTIBIOTIC-RESISTANCE; SEQUENCE-ANALYSIS; BETA-LACTAMASE; FITNESS COSTS; SMEDEF; EMERGENCE; INFECTIONS;
D O I
10.1093/jac/dkz326
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To elucidate the potential mutation-driven mechanisms involved in the acquisition of tigecycline resistance by the opportunistic pathogen Stenotrophomonas maltophilia. The mutational trajectories and their effects on bacterial fitness, as well as cross-resistance and/or collateral susceptibility to other antibiotics, were also addressed. Methods: S. maltophilia populations were submitted to experimental evolution in the presence of increasing concentrations of tigecycline for 30days. The genetic mechanisms involved in the acquisition of tigecycline resistance were determined by WGS. Resistance was evaluated by performing MIC assays. Fitness of the evolved populations and individual clones was assessed by measurement of the maximum growth rates. Results: All the tigecycline-evolved populations attained high-level resistance to tigecycline following different mutational trajectories, yet with some common elements. Among the mechanisms involved in low susceptibility to tigecycline, mutations in the SmeDEF efflux pump negative regulator smeT, changes in proteins involved in the biogenesis of the ribosome and modifications in the LPS biosynthesis pathway seem to play a major role. Besides tigecycline resistance, the evolved populations presented cross-resistance to other antibiotics, such as aztreonam and quinolones, and they were hypersusceptible to fosfomycin, suggesting a possible combination treatment. Further, we found that the selected resistance mechanisms impose a relevant fitness cost when bacteria grow in the absence of antibiotic. Conclusions: Mutational resistance to tigecycline was easily selected during exposure to this antibiotic. However, the fitness cost may compromise the maintenance of S. maltophilia tigecycline-resistant populations in the absence of antibiotic.
引用
收藏
页码:3221 / 3230
页数:10
相关论文
共 50 条
  • [1] Stenotrophomonas maltophilia and tigecycline in clinical practice
    Conde-Estevez, David
    Grau, Santiago
    Alvarez-Lerma, Francisco
    ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA, 2012, 30 (03): : 170 - 171
  • [2] Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections
    Tekce, Yasemin Tezer
    Erbay, Ayse
    Cabadak, Hatice
    Sen, Suha
    JOURNAL OF CHEMOTHERAPY, 2012, 24 (03) : 150 - 154
  • [3] Clinical Factors Associated with Acquisition of Resistance to Levofloxacin in Stenotrophomonas maltophilia
    Baek, Ji Hyeon
    Kim, Chang Oh
    Jeong, Su Jin
    Ku, Nam Soo
    Han, Sang Hoon
    Choi, Jun Yong
    Yong, Dongeun
    Song, Young Goo
    Lee, Kyungwon
    Kim, June Myung
    YONSEI MEDICAL JOURNAL, 2014, 55 (04) : 987 - 993
  • [4] In Vitro Susceptibility of Tigecycline and Colistin Against Stenotrophomonas maltophilia
    Togan, Turhan
    Turan Ozden, Hale
    Azap, Ozlem
    FLORA-INFEKSIYON HASTALIKLARI VE KLINIK MIKROBIYOLOJI DERGISI, 2018, 23 (01): : 25 - 30
  • [5] High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia
    Wu Yuhong
    Shao Zonghong
    CHINESE MEDICAL JOURNAL, 2014, 127 (17) : 3199 - 3199
  • [6] Frequency and Genetic Determinants of Tigecycline Resistance in Clinically Isolated Stenotrophomonas maltophilia in Beijing, China
    Zhao, Jin
    Liu, Yunxi
    Liu, Yi
    Wang, Dong
    Ni, Wentao
    Wang, Rui
    Liu, Youning
    Zhang, Bo
    FRONTIERS IN MICROBIOLOGY, 2018, 9
  • [7] High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia
    Wu Yuhong
    Shao Zonghong
    中华医学杂志(英文版), 2014, (17) : 3199 - 3199
  • [8] Mechanisms of antimicrobial resistance in Stenotrophomonas maltophilia: a review of current knowledge
    Gil-Gil, Teresa
    Martinez, Jose Luis
    Blanco, Paula
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (04) : 335 - 347
  • [9] Stenotrophomonas maltophilia drug resistance
    Sanchez, Maria B.
    Hernandez, Alvaro
    Martinez, Jose L.
    FUTURE MICROBIOLOGY, 2009, 4 (06) : 655 - 660
  • [10] Growing resistance in Stenotrophomonas maltophilia?
    Matson, Hannah H.
    Jones, Bruce M.
    Wagner, Jamie L.
    Motes, Madalyn A.
    Bland, Christopher M.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2019, 76 (24) : 2004 - 2005